Citi lowered the firm’s price target on Ultragenyx (RARE) to $50 from $103 and keeps a Buy rating on the shares. The analyst views the failure of the Orbit and Cosmic studies as a “significant surprise.” Citi cites the removal of setrusumab revenue for the target cut. The firm believes investor patience is now required ahead of Ultragenyx’s gene therapy readouts.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
- Ultragenyx price target lowered to $84 from $105 at Cantor Fitzgerald
- Ultragenyx falls -43.7%
- Ultragenyx: Derisked Valuation and Upcoming Gene Therapy Catalysts Support Maintaining Buy Rating Despite Trial Setback
- William Blair ‘disappointed and surprised’ by Ultragenyx trial news